针对I期肿瘤试验参与者的单中心回顾性得出的预后评分的陷阱与局限性——对富斯尼希等人的回复：一种针对I期癌症患者的新的、简单且客观的预后评分 - Suppr | 超能文献

Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients.

作者信息

Olmos David, Ang Joo Ern, Gomez-Roca Carlos, Morales-Barrera Rafael, Vulink Annelie J, Massard Christophe, Kaye Stan

出版信息

Eur J Cancer. 2012 Mar;48(4):594-6. doi: 10.1016/j.ejca.2011.11.004. Epub 2011 Dec 7.

DOI:10.1016/j.ejca.2011.11.004

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients.针对I期肿瘤试验参与者的单中心回顾性得出的预后评分的陷阱与局限性——对富斯尼希等人的回复：一种针对I期癌症患者的新的、简单且客观的预后评分

Eur J Cancer. 2012 Mar;48(4):594-6. doi: 10.1016/j.ejca.2011.11.004. Epub 2011 Dec 7.

2

Reply letter to: pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant - reply to Füssenich et al.: a new, simple and objective prognostic score for phase I cancer patients.致《I期肿瘤试验参与者单中心回顾性得出的预后评分的陷阱与局限性——对Füssenich等人的回复：一种针对I期癌症患者的新的、简单且客观的预后评分》的回复信

Eur J Cancer. 2012 Mar;48(4):597-8. doi: 10.1016/j.ejca.2012.01.020.

3

A new, simple and objective prognostic score for phase I cancer patients.一种用于 I 期癌症患者的新型、简单且客观的预后评分系统。

Eur J Cancer. 2011 May;47(8):1152-60. doi: 10.1016/j.ejca.2010.12.028. Epub 2011 Feb 25.

4

Reply to D. Milne et al.对D. 米尔恩等人的回复

J Clin Oncol. 2013 Jun 1;31(16):2055-6. doi: 10.1200/JCO.2013.49.1894.

5

Some notable properties of the standard oncology Phase I design.标准肿瘤学I期设计的一些显著特性。

J Biopharm Stat. 2009;19(3):543-55. doi: 10.1080/10543400902802466.

6

New requirements for phase I trials: a challenge for Italian clinical research.I期试验的新要求：对意大利临床研究的一项挑战。

Tumori. 2018 Jan-Feb;104(1):15-21. doi: 10.5301/tj.5000668.

7

New adaptive method for phase I trials in oncology.肿瘤学I期试验的新型自适应方法。

Clin Pharmacol Ther. 2008 Jun;83(6):873-81. doi: 10.1038/sj.clpt.6100383. Epub 2007 Oct 24.

8

Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.重新审视儿科肿瘤I期临床试验中剂量限制毒性的定义：来自儿童癌症创新疗法联盟的分析

Eur J Cancer. 2017 Nov;86:275-284. doi: 10.1016/j.ejca.2017.09.015. Epub 2017 Oct 19.

9

Practical designs for Phase I combination studies in oncology.肿瘤学中I期联合研究的实用设计。

J Biopharm Stat. 2016;26(1):150-66. doi: 10.1080/10543406.2015.1092029.

10

The changing landscape of phase I trials in oncology.肿瘤学I期试验不断变化的格局。

Am Soc Clin Oncol Educ Book. 2015:3-8. doi: 10.14694/EdBook_AM.2015.35.3.

引用本文的文献

1

Survival and new-onset morbidity after critical care admission for acute pancreatitis in Scotland: a national electronic healthcare record linkage cohort study.苏格兰急性胰腺炎重症监护入院后的生存情况及新发疾病：一项全国性电子健康记录关联队列研究。

BMJ Open. 2018 Dec 14;8(12):e023853. doi: 10.1136/bmjopen-2018-023853.

2

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.帕唑帕尼治疗晚期软组织肉瘤的长期缓解者和幸存者：欧洲癌症研究与治疗组织（EORTC）两项临床试验62043和62072的亚组分析

Ann Oncol. 2014 Mar;25(3):719-724. doi: 10.1093/annonc/mdt586. Epub 2014 Feb 6.

3

An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.基于炎症的评分可以优化考虑早期临床试验的晚期癌症患者的选择。

PLoS One. 2014 Jan 7;9(1):e83279. doi: 10.1371/journal.pone.0083279. eCollection 2014.